- Home
- AVTX vs STRO Comparison
AVTX vs STRO Comparison
Compare AVTX & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AVTX | STRO |
|---|---|---|
| Founded | 2011 | 2003 |
| Country | United States | United States |
| Employees | N/A | 131 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 339.9M | 338.9M |
| IPO Year | 2015 | N/A |
Fundamental Metrics
Financial Performance| Metric | AVTX | STRO |
|---|---|---|
| Price | $14.95 | $24.83 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 8 |
| Target Price | ★ $36.80 | $26.38 |
| AVG Volume (30 Days) | ★ 745.9K | 168.4K |
| Earning Date | 03-23-2026 | 03-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 72.07 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $27,813,137.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $13.45 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 2312.27 | N/A |
| 52 Week Low | $3.39 | $0.52 |
| 52 Week High | $20.72 | $27.96 |
Technical Indicators
Market Signals| Indicator | AVTX | STRO |
|---|---|---|
| Relative Strength Index (RSI) | 48.97 | 62.71 |
| Support Level | $13.38 | $0.76 |
| Resistance Level | $16.40 | $27.96 |
| Average True Range (ATR) | 1.08 | 2.18 |
| MACD | -0.09 | -0.09 |
| Stochastic Oscillator | 48.03 | 77.04 |
Price Performance
Historical ComparisonAbout AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.